Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) is a Healthcare company (Biotechnology) with a market capitalization of $230M. The Maz Rating grades it against the other companies in its sector.
Arcturus Therapeutics Holdings Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $7.97, Arcturus Therapeutics Holdings Inc. trades at 9.1x sales and 1.3x book value. Over the last twelve months it generated about $25M of revenue and a net loss of $90M. It runs a gross margin of 97.4%, an operating margin of -384.1% and a net margin of -349.7%. It shows return on equity of -46.8%, return on invested capital of -50.3% and a free cash flow yield of -27.4%. On the balance sheet: a debt-to-equity ratio of 0.13 and a current ratio of 6.68. Over the past 52 weeks the share price ranged from $5.50 to $17.96, with a beta of 2.60.
Arcturus Therapeutics Holdings Inc. does not currently pay a dividend.
21 Wall Street analyst ratings cover the stock: 12 Buy, 5 Hold and 4 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.